286 related articles for article (PubMed ID: 24971074)
1. Brain morphometry and the neurobiology of levodopa-induced dyskinesias: current knowledge and future potential for translational pre-clinical neuroimaging studies.
Finlay CJ; Duty S; Vernon AC
Front Neurol; 2014; 5():95. PubMed ID: 24971074
[TBL] [Abstract][Full Text] [Related]
2. Morphological and electrophysiological changes in intratelencephalic-type pyramidal neurons in the motor cortex of a rat model of levodopa-induced dyskinesia.
Ueno T; Yamada J; Nishijima H; Arai A; Migita K; Baba M; Ueno S; Tomiyama M
Neurobiol Dis; 2014 Apr; 64():142-9. PubMed ID: 24398173
[TBL] [Abstract][Full Text] [Related]
3. Prefrontal thickening in PD with levodopa-induced dyskinesias: new evidence from cortical thickness measurement.
Cerasa A; Morelli M; Augimeri A; Salsone M; Novellino F; Gioia MC; Arabia G; Quattrone A
Parkinsonism Relat Disord; 2013 Jan; 19(1):123-5. PubMed ID: 22742954
[TBL] [Abstract][Full Text] [Related]
4. Flow-metabolism dissociation in the pathogenesis of levodopa-induced dyskinesia.
Jourdain VA; Tang CC; Holtbernd F; Dresel C; Choi YY; Ma Y; Dhawan V; Eidelberg D
JCI Insight; 2016 Sep; 1(15):e86615. PubMed ID: 27699242
[TBL] [Abstract][Full Text] [Related]
5. A network centred on the inferior frontal cortex is critically involved in levodopa-induced dyskinesias.
Cerasa A; Koch G; Donzuso G; Mangone G; Morelli M; Brusa L; Stampanoni Bassi M; Ponzo V; Picazio S; Passamonti L; Salsone M; Augimeri A; Caltagirone C; Quattrone A
Brain; 2015 Feb; 138(Pt 2):414-27. PubMed ID: 25414038
[TBL] [Abstract][Full Text] [Related]
6. [Dyskinesia in Parkinson's disease: an update on new neuroimaging methods and treatment possibilities].
Thomsen BL; Herz DM; Siebner HR; Løkkegaard A
Ugeskr Laeger; 2017 Mar; 179(10):. PubMed ID: 28263159
[TBL] [Abstract][Full Text] [Related]
7. Presynaptic dopamine depletion determines the timing of levodopa-induced dyskinesia onset in Parkinson's disease.
Yoo HS; Chung SJ; Chung SJ; Moon H; Oh JS; Kim JS; Hong JY; Ye BS; Sohn YH; Lee PH
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):423-431. PubMed ID: 29075830
[TBL] [Abstract][Full Text] [Related]
8. Brain-Region Specific Metabolic Abnormalities in Parkinson's Disease and Levodopa-Induced Dyskinesia.
Yang C; Zhang T; Wang W; Xiang Y; Huang Q; Xie C; Zhao L; Zheng H; Yang Y; Gao H
Front Aging Neurosci; 2020; 12():75. PubMed ID: 32256342
[TBL] [Abstract][Full Text] [Related]
9. Levodopa-induced dyskinesia in Parkinson's disease.
Brotchie JM; Lee J; Venderova K
J Neural Transm (Vienna); 2005 Mar; 112(3):359-91. PubMed ID: 15614429
[TBL] [Abstract][Full Text] [Related]
10. Age at onset influences neurodegenerative processes underlying PD with levodopa-induced dyskinesias.
Cerasa A; Salsone M; Morelli M; Pugliese P; Arabia G; Gioia CM; Novellino F; Quattrone A
Parkinsonism Relat Disord; 2013 Oct; 19(10):883-8. PubMed ID: 23769805
[TBL] [Abstract][Full Text] [Related]
11. Neurosurgical Approaches to Levodopa-Induced Dyskinesia.
Martini ML; Mocco J; Panov F
World Neurosurg; 2019 Jun; 126():376-382. PubMed ID: 30880213
[TBL] [Abstract][Full Text] [Related]
12. Force overflow and levodopa-induced dyskinesias in Parkinson's disease.
Wenzelburger R; Zhang BR; Pohle S; Klebe S; Lorenz D; Herzog J; Wilms H; Deuschl G; Krack P
Brain; 2002 Apr; 125(Pt 4):871-9. PubMed ID: 11912119
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetic profile and the development of the dyskinesia induced by levodopa-therapy in Parkinson's disease patients: a population-based cohort study.
Dos Santos EUD; da Silva IIFG; Asano AGC; Asano NMJ; De Mascena Diniz Maia M; de Souza PRE
Mol Biol Rep; 2020 Nov; 47(11):8997-9004. PubMed ID: 33151475
[TBL] [Abstract][Full Text] [Related]
14. Impulse Control Disorders and Levodopa-Induced Dyskinesias in Parkinson's Disease: Pulsatile versus Continuous Dopaminergic Stimulation.
Simoni S; Paoletti FP; Eusebi P; Cappelletti G; Filidei M; Brahimi E; Nigro P; Santangelo V; Parnetti L; Calabresi P; Tambasco N
J Parkinsons Dis; 2020; 10(3):927-934. PubMed ID: 32280105
[TBL] [Abstract][Full Text] [Related]
15. Dyskinesia and brain-derived neurotrophic factor levels after long-term levodopa and nicotinic receptor agonist treatments in female mice with near-total unilateral dopaminergic denervation.
Leino S; Kohtala S; Rantamäki T; Koski SK; Rannanpää S; Salminen O
BMC Neurosci; 2018 Nov; 19(1):77. PubMed ID: 30497382
[TBL] [Abstract][Full Text] [Related]
16. Dystonia and levodopa-induced dyskinesias in Parkinson's disease: Is there a connection?
Calabresi P; Standaert DG
Neurobiol Dis; 2019 Dec; 132():104579. PubMed ID: 31445160
[TBL] [Abstract][Full Text] [Related]
17. A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease.
van der Stelt M; Fox SH; Hill M; Crossman AR; Petrosino S; Di Marzo V; Brotchie JM
FASEB J; 2005 Jul; 19(9):1140-2. PubMed ID: 15894565
[TBL] [Abstract][Full Text] [Related]
18. Chemical management of levodopa-induced dyskinesia in Parkinson's disease patients.
Dragašević-Mišković N; Petrović I; Stanković I; Kostić VS
Expert Opin Pharmacother; 2019 Feb; 20(2):219-230. PubMed ID: 30411647
[TBL] [Abstract][Full Text] [Related]
19. Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease.
Duty S
CNS Drugs; 2012 Dec; 26(12):1017-32. PubMed ID: 23114872
[TBL] [Abstract][Full Text] [Related]
20. Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment.
Thanvi B; Lo N; Robinson T
Postgrad Med J; 2007 Jun; 83(980):384-8. PubMed ID: 17551069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
